Ranibizumab

Chemical formula: C₂₁₅₈H₃₂₈₂N₅₆₂O₆₈₁S₁₂ 

Active ingredient description

Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO in adults and retinopathy of prematurity in preterm infants.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
S01LA04 Ranibizumab S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA04

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
LUCENTIS Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 347396-82-1
DrugBank Drug: DB01270
KEGG Drug: D05697
RxNorm Ingredient: 595060
SNOMED-CT Concept: 422456007
Ranibizumab (substance)
UNII Identifier: ZL1R02VT79
RANIBIZUMAB

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.